Spironolactone is not Effective for the Treatment of Hypokalemia in Peritoneal Dialysis Patients  by Kwok, Jeffrey Sung-Shing et al.
36 Hong Kong J Nephrol • April 2007 • Vol 9 • No 1
Original Article
INTRODUCTION
Hypokalemia is a common complication among
pat ients  undergoing cont inuous ambulatory
peritoneal dialysis (CAPD). It is found in 10–36%
of CAPD patients [1–3], and may be associated with
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Background: Hypokalemia is a common problem in patients on continuous ambulatory peritoneal dialysis
(CAPD). We evaluated the efficacy and safety of spironolactone in CAPD patients with hypokalemia.
Methods: We reviewed the clinical response of 12 consecutive hypokalemic CAPD patients treated with
spironolactone in our dialysis center.
Results: All patients received spironolactone 25 mg daily. There was no significant change in the serum
potassium level after administration of spironolactone (3.30 ± 0.26 vs. 3.46 ± 0.38 mmol/L, p = 0.28), even
though three patients required regular oral potassium supplementation. There was also no significant change in
arterial blood pressure or urine output after spironolactone treatment. Spironolactone was well tolerated and
no hyperkalemia was recorded.
Conclusion: Spironolactone is not effective in the treatment of hypokalemia in stable CAPD patients, but the
agent is well tolerated, at least in CAPD patients with little residual renal function. Future studies are warranted
to determine the therapeutic role of spironolactone in CAPD patients with concomitant congestive heart failure
or cardiovascular disease. [Hong Kong J Nephrol 2007;9(1):36–40]
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increased cardiac morbidity and mortality in such
patients [4]. The recommended serum potassium
concentration is 3.0 mmol/L and above in asymp-
tomatic patients, and greater than 3.5 mmol/L in
patients taking digoxin or with a history of cardiac
arrhythmias [5].
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Hypoka lemia  can  be  co r rec ted  by  o ra l
supplementation and/or intraperitoneal potassium
administration. The compliance of potassium
supplementation, however, is often poor. Although
potassium loss in the dialysate and poor oral intake are
the major causes of hypokalemia in most patients,
gastrointestinal loss is often considerable [6–10]. In
fact, potassium conductance is present in colonic
epithelium [11], and colonic potassium excretion is
under the influence of renin-angiotensin-aldosterone
axis [12,13]. In this study, we evaluated the efficacy
and safety of spironolactone, an aldosterone antagonist,
in CAPD patients with hypokalemia.
PATIENTS AND METHODS
We reviewed 12 consecutive hypokalemic CAPD
patients treated with spironolactone from January 2003
to September 2004 in our dialysis center. Serum
potassium levels were measured in the patients every
4–8 weeks as decided by their nephrologists. Hypo-
kalemia was defined as serum potassium level be-
low 3.0 mmol/L. Baseline data including age, gender,
comorbidities, underlying renal diagnosis, duration of
dialysis, duration and dosage of spironolactone, were
recorded. Average blood pressure and serum potassium
levels, 6 months before and after spironolactone
treatment, were computed. Dialysis adequacy indices,
daily ultrafiltration volume, urine output, residual renal
function, and the use of medications that might affect
potassium balance, including diuretics, potassium
supplement and angiotensin-converting enzyme (ACE)
inhibitor, were also reviewed. Residual glomerular
filtration rate (GFR) was calculated as an average of
24-hour urinary urea and creatinine clearance [14].
Statistical analysis
Statistical analysis was performed using SPSS version
11.0 (SPSS Inc., Chicago, IL, USA) for Windows.
Results are expressed as mean ± standard deviation
unless otherwise specified. Comparisons between pre-
and post-spironolactone data were performed using
paired Student’s t test. Correlations between continuous
variables were assessed by Spearman’s rank correlation
test (r = correlation coefficient). A p value of less than
0.05 was considered statistically significant. All
probabilities were two-tailed.
RESULTS
The baseline demographic and clinical characteristics
of the 12 patients are summarized in Table 1. Patient
demographics were similar to that of the CAPD
population of our dialysis unit as published previously
[15,16]. The baseline serum potassium level was 3.30
± 0.26 mmol/L. Five patients required regular oral
potassium supplementation; the average dosage was
19 ± 7 mmol per day. Six patients received frusemide;
the average dose was 222 ± 69 mg per day. Of the seven
patients with preexisting cardiovascular diseases, five
were on concomitant ACE inhibitor therapy.
All patients received spironolactone 25 mg daily;
the median duration of treatment was 20 weeks
(range, 8–26 weeks). After 3 months of spironolactone
therapy, there was an insignificant increase in average
serum potassium level from 3.30 ± 0.26 to 3.46 ± 0.38
mmol/L (Table 2) (paired Student’s t test, p = 0.28).
Table 1. Demographic and baseline clinical data of the patients
(n = 12)
Sex (M:F) 1:11
Age (yr) 57.8 ± 17.9
Duration of dialysis (mo) 44.6 ± 35.7
Body height (cm) 155.2 ± 7.3
Body weight (kg) 52.9 ± 6.1
Mean blood pressure (mmHg) 101.9 ± 16.5
Renal diagnosis (n)
Glomerulonephritis 2
Diabetic nephropathy 6
Polycystic kidney 1
Others/unknown 3
Table 2. Residual renal function, dialysis adequacy indices and nutritional parameters at baseline and 6 months after spironolactone treatment
Baseline 6 months after treatment p
Daily urine output (L/day) 0.53 ± 0.75 0.27 ± 0.52 0.021
Residual GFR (mL/min/1.73 m2) 1.59 ± 1.88 0.67 ± 1.02 0.014
Daily exchange volume (L/day) 6.17 ± 0.58 6.33 ± 0.78 0.8
Daily ultrafiltration volume (L/day) 0.99 ± 0.58 0.36 ± 0.61 0.01
Weekly total Kt/V 2.04 ± 0.55 1.97 ± 0.34 0.5
NPNA (g/kg/day) 1.02 ± 0.30 0.94 ± 0.26 0.4
Serum albumin (g/L) 31.7 ± 3.7 31.4 ± 5.6 0.9
GFR = glomerular filtration rate; Kt/V = index of dialysis adequacy; NPNA = normalized protein nitrogen appearance.
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Changes in serum potassium of individual patients are
depicted in Figure 1. Two patients no longer required
oral potassium supplement, while three others were still
dependent on regular supplementation with the average
dosage at 13 ± 5 mmol per day. After spironolactone
treatment, there was no significant change in the mean
arterial blood pressure (102 ± 17 vs. 102 ± 15 mmHg;
p = 0.97). Changes in mean arterial blood pressure of
individual patients are depicted in Figure 2. The change
in serum potassium level was slightly less in patients
with diabetes (0.12 ± 0.53 vs. 0.20 ± 0.49 mmol/L; p =
0.5) or with concomitant loop diuretic therapy (0.13 ±
0.46 vs. 0.18 ± 0.56 mmol/L; p = 0.6). The increase in
serum potassium level was more marked in patients on
oral potassium supplement (0.29 ± 0.75 vs. 0.06 ± 0.19
mmol/L; p = 0.6) or ACE inhibitor treatment (0.27 ±
0.55 vs. 0.05 ± 0.44 mmol/L; p = 0.2). None of the
results reached statistical significance because of the
small sample size. Serum potassium level after
spironolactone treatment was not related to baseline
urine output (r = –0.212, p = 0.5) or residual GFR
(r = –0.282, p = 0.4).
Spironolactone was well tolerated amongst our
CAPD patients and no adverse effect was reported. No
episode of hyperkalemia was noted during the period
of spironolactone treatment.
DISCUSSION
In this study, we found no significant change in the
serum potassium level of CAPD patients after
administration of spironolactone. Our results indicate
that spironolactone is not effective in the treatment of
hypokalemia in CAPD patients. Nevertheless,
spironolactone was well tolerated with minimal adverse
effects in this group of patients. These results suggest
that low-dose spironolactone may be administered with
caution to CAPD patients with cardiovascular
indications.
The use of aldosterone antagonist in renal patients
has become a hot topic recently. Coronary artery disease
and congestive heart failure are common in patients
with chronic kidney diseases [17] and those on dialysis
[18,19]. The renin-angiotensin-aldosterone system
plays a key role in the pathophysiology of congestive
heart failure [20,21]. Aldosterone does not only pro-
mote salt retention, but is also an important mediator
of  myocardial  col lagen deposi t ion [22,23].
Spironolactone, a competitive inhibitor of aldosterone,
reduces the mortality and morbidity in patients with
congestive heart failure [24–26]. The indiscriminate
prescription of spironolactone, however, has recently
been implicated in causing an increase in hyperkalemia-
associated morbidity and mortality, especially in
patients with preexisting renal impairment [27].
Therefore, spironolactone is generally contraindicated
in patients with advanced renal insufficiency.
Reports are scanty on the use of spironolactone in
dialysis patients [28,29]. Our result is similar to that of
Saudan et  al  [28] who found that  low-dose
spironolactone did not change the mean serum
potassium level or was not associated with an increased
frequency of hyperkalemia in hemodialysis patients.
An accompanying editorial to the study by Saudan
et al concluded that spironolactone can be safely
Figure 1. Serum potassium levels before and after
spironolactone treatment.
Figure 2. Mean arterial blood pressure before and after
spironolactone treatment.
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administered to stable hemodialysis patients, and may
be considered as a treatment option for chronic
hemodialysis patients with heart disease [29]. It is
generally agreed that peritoneal dialysis is less effective
in removing potassium, and our results suggest that this
can probably be extrapolated to CAPD patients.
There are several limitations to our study. Because
of the small sample size of our study, we did not have
adequate statistical power to detect a small but
physiologically significant change in serum potassium
level. We did not assess the compliance to spiro-
nolactone treatment or potassium supplement. The
retrospective nature of this study did not allow us to
perform detailed balance study on the potassium intake
and the change in urinary, dialysate, and gastrointestinal
loss of potassium before and after spironolactone
treatment. As none of our patients had chronic diarrhea
or vomiting, and the average daily urine output was
less than 700 mL, the lack of effect of spironolactone
suggested that poor dietary intake was probably the
major cause of hypokalemia in our patients. It is
important to note that most of the patients in this series
had little residual renal function. Therefore, one needs
to be cautious when extrapolating our results to patients
with substantial residual renal function.
In summary, we found that spironolactone had
negligible effect on the serum potassium level of stable
CAPD patients. Spironolactone was well tolerated in
these patients with minimal residual renal function. The
therapeutic role of spironolactone in CAPD patients
with congestive heart failure or other cardiovascular
diseases may warrant further study.
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